Selected research
Industry Research
Plasma Fractionation and Blood Product Industry Research Report 2026
Market perspective
The global Plasma Fractionation and Blood Product market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Plasma Fractionation and Blood Product is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Plasma Fractionation and Blood Product is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Plasma Fractionation and Blood Product is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Plasma Fractionation and Blood Product include Takeda, RAAS, Octapharma, LFB Group, Kedrion, Hualan Bio, Grifols, CSL and CBPO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Plasma Fractionation and Blood Product market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Plasma Fractionation and Blood Product Market by Company
Takeda
RAAS
Octapharma
LFB Group
Kedrion
Hualan Bio
Grifols
CSL
CBPO
BPL
Biotest
Plasma Fractionation and Blood Product Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Other
Plasma Fractionation and Blood Product Segment by Application
Immunology
Hematology
Other
Plasma Fractionation and Blood Product Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Fractionation and Blood Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Fractionation and Blood Product and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Fractionation and Blood Product.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Plasma Fractionation and Blood Product manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Plasma Fractionation and Blood Product by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Plasma Fractionation and Blood Product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Albumin
- Immune Globulin
- Coagulation Factor
- Other
Applications
- Immunology
- Hematology
- Other
Companies covered
- Takeda
- RAAS
- Octapharma
- LFB Group
- Kedrion
- Hualan Bio
- Grifols
- CSL
- CBPO
- BPL
- Biotest
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Plasma Fractionation and Blood Product Market Size (2021-2032)
- 2.2.2 Global Plasma Fractionation and Blood Product Sales (2021-2032)
- 2.2.3 Global Plasma Fractionation and Blood Product Market Average Price (2021-2032)
- 2.3 Plasma Fractionation and Blood Product by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Albumin
- 2.3.3 Immune Globulin
- 2.3.4 Coagulation Factor
- 2.3.5 Other
- 2.4 Plasma Fractionation and Blood Product by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Immunology
- 2.4.3 Hematology
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Plasma Fractionation and Blood Product Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Plasma Fractionation and Blood Product Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Plasma Fractionation and Blood Product Revenue of Manufacturers (2021-2026)
- 3.4 Global Plasma Fractionation and Blood Product Average Price by Manufacturers (2021-2026)
- 3.5 Global Plasma Fractionation and Blood Product Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Plasma Fractionation and Blood Product, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Plasma Fractionation and Blood Product, Product Type & Application
- 3.8 Global Manufacturers of Plasma Fractionation and Blood Product, Established Date
- 3.9 Global Plasma Fractionation and Blood Product Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Plasma Fractionation and Blood Product Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 RAAS
- 4.2.1 RAAS Company Information
- 4.2.2 RAAS Business Overview
- 4.2.3 RAAS Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 RAAS Plasma Fractionation and Blood Product Product Portfolio
- 4.2.5 RAAS Recent Developments
- 4.3 Octapharma
- 4.3.1 Octapharma Company Information
- 4.3.2 Octapharma Business Overview
- 4.3.3 Octapharma Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Octapharma Plasma Fractionation and Blood Product Product Portfolio
- 4.3.5 Octapharma Recent Developments
- 4.4 LFB Group
- 4.4.1 LFB Group Company Information
- 4.4.2 LFB Group Business Overview
- 4.4.3 LFB Group Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 LFB Group Plasma Fractionation and Blood Product Product Portfolio
- 4.4.5 LFB Group Recent Developments
- 4.5 Kedrion
- 4.5.1 Kedrion Company Information
- 4.5.2 Kedrion Business Overview
- 4.5.3 Kedrion Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kedrion Plasma Fractionation and Blood Product Product Portfolio
- 4.5.5 Kedrion Recent Developments
- 4.6 Hualan Bio
- 4.6.1 Hualan Bio Company Information
- 4.6.2 Hualan Bio Business Overview
- 4.6.3 Hualan Bio Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Bio Plasma Fractionation and Blood Product Product Portfolio
- 4.6.5 Hualan Bio Recent Developments
- 4.7 Grifols
- 4.7.1 Grifols Company Information
- 4.7.2 Grifols Business Overview
- 4.7.3 Grifols Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Grifols Plasma Fractionation and Blood Product Product Portfolio
- 4.7.5 Grifols Recent Developments
- 4.8 CSL
- 4.8.1 CSL Company Information
- 4.8.2 CSL Business Overview
- 4.8.3 CSL Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSL Plasma Fractionation and Blood Product Product Portfolio
- 4.8.5 CSL Recent Developments
- 4.9 CBPO
- 4.9.1 CBPO Company Information
- 4.9.2 CBPO Business Overview
- 4.9.3 CBPO Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CBPO Plasma Fractionation and Blood Product Product Portfolio
- 4.9.5 CBPO Recent Developments
- 4.10 BPL
- 4.10.1 BPL Company Information
- 4.10.2 BPL Business Overview
- 4.10.3 BPL Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 BPL Plasma Fractionation and Blood Product Product Portfolio
- 4.10.5 BPL Recent Developments
- 4.11 Biotest
- 4.11.1 Biotest Company Information
- 4.11.2 Biotest Business Overview
- 4.11.3 Biotest Plasma Fractionation and Blood Product Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biotest Plasma Fractionation and Blood Product Product Portfolio
- 4.11.5 Biotest Recent Developments
5 Global Plasma Fractionation and Blood Product Market Scenario by Region
- 5.1 Global Plasma Fractionation and Blood Product Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Plasma Fractionation and Blood Product Sales by Region: 2021-2032
- 5.2.1 Global Plasma Fractionation and Blood Product Sales by Region: 2021-2026
- 5.2.2 Global Plasma Fractionation and Blood Product Sales by Region: 2027-2032
- 5.3 Global Plasma Fractionation and Blood Product Revenue by Region: 2021-2032
- 5.3.1 Global Plasma Fractionation and Blood Product Revenue by Region: 2021-2026
- 5.3.2 Global Plasma Fractionation and Blood Product Revenue by Region: 2027-2032
- 5.4 North America Plasma Fractionation and Blood Product Market Facts & Figures by Country
- 5.4.1 North America Plasma Fractionation and Blood Product Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Plasma Fractionation and Blood Product Sales by Country (2021-2032)
- 5.4.3 North America Plasma Fractionation and Blood Product Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Plasma Fractionation and Blood Product Market Facts & Figures by Country
- 5.5.1 Europe Plasma Fractionation and Blood Product Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Plasma Fractionation and Blood Product Sales by Country (2021-2032)
- 5.5.3 Europe Plasma Fractionation and Blood Product Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Plasma Fractionation and Blood Product Market Facts & Figures by Country
- 5.6.1 Asia Pacific Plasma Fractionation and Blood Product Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Plasma Fractionation and Blood Product Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Plasma Fractionation and Blood Product Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Plasma Fractionation and Blood Product Market Facts & Figures by Country
- 5.7.1 South America Plasma Fractionation and Blood Product Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Plasma Fractionation and Blood Product Sales by Country (2021-2032)
- 5.7.3 South America Plasma Fractionation and Blood Product Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Plasma Fractionation and Blood Product Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Plasma Fractionation and Blood Product Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Plasma Fractionation and Blood Product Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Plasma Fractionation and Blood Product Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Plasma Fractionation and Blood Product Sales by Type (2021-2032)
- 6.1.1 Global Plasma Fractionation and Blood Product Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Plasma Fractionation and Blood Product Sales Market Share by Type (2021-2032)
- 6.2 Global Plasma Fractionation and Blood Product Revenue by Type (2021-2032)
- 6.2.1 Global Plasma Fractionation and Blood Product Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Plasma Fractionation and Blood Product Revenue Market Share by Type (2021-2032)
- 6.3 Global Plasma Fractionation and Blood Product Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Plasma Fractionation and Blood Product Sales by Application (2021-2032)
- 7.1.1 Global Plasma Fractionation and Blood Product Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Plasma Fractionation and Blood Product Sales Market Share by Application (2021-2032)
- 7.2 Global Plasma Fractionation and Blood Product Revenue by Application (2021-2032)
- 7.2.1 Global Plasma Fractionation and Blood Product Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Plasma Fractionation and Blood Product Revenue Market Share by Application (2021-2032)
- 7.3 Global Plasma Fractionation and Blood Product Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Plasma Fractionation and Blood Product Value Chain Analysis
- 8.1.1 Plasma Fractionation and Blood Product Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Plasma Fractionation and Blood Product Production Mode & Process
- 8.2 Plasma Fractionation and Blood Product Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Plasma Fractionation and Blood Product Distributors
- 8.2.3 Plasma Fractionation and Blood Product Customers
9 Global Plasma Fractionation and Blood Product Analyzing Market Dynamics
- 9.1 Plasma Fractionation and Blood Product Industry Trends
- 9.2 Plasma Fractionation and Blood Product Industry Drivers
- 9.3 Plasma Fractionation and Blood Product Industry Opportunities and Challenges
- 9.4 Plasma Fractionation and Blood Product Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst